VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesMarketEarningsCompareWatchlistInsider
DCTHDelcath Systems, Inc.
$11.69$404M
Research
Overview
Valuation
ValuationTargetsPrice
Financials
RevenueEarningsP/ERatiosDividend
Ownership
Holders
Tools
Total ReturnDCA Calculator
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

Follow VCP Scanner on XFollow VCP Scanner on LinkedIn
© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist

DCTH logoDelcath Systems, Inc.(DCTH)Earnings, Financials & Key Ratios

DCTH•NASDAQ
172.9× P/E·Price updated Jun 19, 2026
SectorHealthcareIndustryMedical DevicesSub-IndustryImaging, radiation, and oncology devices
AboutDelcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.Show more
  • Revenue$85M+129.1%
  • EBITDA$1M+108.3%
  • Net Income$3M+110.2%
  • EPS (Diluted)0.07+107.3%
  • Gross Margin86.16%+3.3%
  • EBITDA Margin1.18%+103.6%
  • Operating Margin0.77%+102.3%
  • Net Margin3.17%+104.5%
  • ROE3%+104.8%

DCTH Key Insights

Delcath Systems, Inc. (DCTH) fundamental analysis — strengths, weaknesses & financial health based on data analysis

✓Strengths

  • ✓Company is almost debt free
  • ✓Strong Piotroski F-Score: 7/9
  • ✓FCF machine: 24.6% free cash flow margin
  • ✓High quality earnings: Operating CF exceeds net income
  • ✓Strong 5Y sales CAGR of 120.2%

✗Weaknesses

  • ✗Shares diluted 40.0% in last year

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

Get notified when DCTH posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

DCTH Price & Volume

Delcath Systems, Inc. (DCTH) stock price & volume — 10-year historical chart

Loading chart...

DCTH Growth Metrics

Delcath Systems, Inc. (DCTH) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years47.51%
5 Years120.21%
3 Years215.3%
TTM67.95%

Profit CAGR

10 Years-
5 Years-
3 Years-
TTM103.95%

EPS CAGR

10 Years-
5 Years-
3 Years-
TTM101.19%

Return on Capital

10 Years-2244.85%
5 Years-129.25%
3 Years-109.34%
Last Year0.72%

DCTH Peer Comparison

Delcath Systems, Inc. (DCTH) competitors in Imaging, radiation, and oncology devices — business model, growth, and fundamentals comparison

Select Columns
Stock Universe
Valuation
Growth
Profitability
Financial Health
Dividends & Buybacks
Price Performance
Technical
Fundamentals ($)
Sector-Specific
Institutional Holdings
CompanyMarket CapStock PriceP/E Ratio (TTM)Revenue Growth 1YNet MarginReturn on Equity (ROE)FCF YieldDebt / Equity
NVCR logoNVCRNovoCure LimitedDirect Competitor1.62B14.28-11.708.28%-25.66%-50.82%0.85
AGEN logoAGENAgenus Inc.Direct Competitor124.93M3.00-882.3510.37%52.16%
CLDX logoCLDXCelldex Therapeutics, Inc.Direct Competitor2.16B32.43-8.32-78.63%-345.96%-50.72%0.00
IMVT logoIMVTImmunovant, Inc.Direct Competitor7.26B35.34-12.76-68.16%0.00
HALO logoHALOHalozyme Therapeutics, Inc.Product Competitor8.13B68.5526.7837.55%23.13%126.27%43.89
INVA logoINVAInnoviva, Inc.Product Competitor1.66B22.496.8218.52%118.91%47.59%0.23
TGTX logoTGTXTG Therapeutics, Inc.Product Competitor8.15B53.2219.2187.32%65.95%87.36%0.40
RCUS logoRCUSArcus Biosciences, Inc.Product Competitor2.45B24.31-7.39-4.26%-156.36%-68.97%0.16

Compare DCTH vs Peers

Delcath Systems, Inc. (DCTH) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs NVCR

Most directly comparable listed peer for DCTH.

Scale Benchmark

vs ISRG

Larger-name benchmark to compare DCTH against a more recognizable public peer.

Peer Set

Compare Top 5

vs NVCR, AGEN, CLDX, IMVT

DCTH Income Statement

Delcath Systems, Inc. (DCTH) annual income statement — 10-year revenue, gross profit & net income history

10Y historyFree accessUpdated daily
MetricDec'17Dec'18Dec'19Dec'20Dec'21Dec'22Dec'23Dec'24Dec'25TTM
Sales/Revenue
2.71M3.41M1.58M1.65M3.56M2.72M2.06M37.2M85.23M90.44M
Revenue Growth %
36.3%25.49%-53.62%4.18%115.98%-23.52%-24.05%1701.69%129.08%67.95%
Cost of Goods Sold
701K1.01M719K640K671K686K635K6.19M11.8M12.69M
COGS % of Revenue
25.82%29.62%45.51%38.88%18.87%25.23%30.75%16.63%13.84%-
Gross Profit
2.01M▲ 0%
2.4M▲ 19.1%
861K▼ 64.1%
1.01M▲ 16.8%
2.88M▲ 186.7%
2.03M▼ 29.5%
1.43M▼ 29.7%
31.02M▲ 2069.0%
73.43M▲ 136.8%
77.75M▲ 0%
Gross Margin %
74.18%70.38%54.49%61.12%81.13%74.77%69.25%83.37%86.16%85.97%
Gross Profit Growth %
39.67%19.07%-64.1%16.84%186.68%-29.51%-29.66%2069.02%136.75%-
Operating Expenses
20.18M29.47M20.77M22.31M27.41M35.89M39.61M43.43M72.77M79.37M
OpEx % of Revenue
743.24%864.95%1314.49%1355.35%771.17%1319.82%1918.26%116.72%85.38%-
Selling, General & Admin
9.68M9.82M11.28M11.11M13.64M17.3M22.11M29.55M43.53M45.31M
SG&A % of Revenue
356.69%288.2%713.86%674.85%383.6%636.37%1070.7%79.43%51.07%-
Research & Development
10.49M19.65M9.49M11.2M13.78M18.58M17.5M13.87M29.25M34.06M
R&D % of Revenue
386.56%576.75%600.63%680.5%387.57%683.45%847.55%37.29%34.31%-
Other Operating Expenses
-41K51K00000000
Operating Income
-18.16M▲ 0%
-27.07M▼ 49.0%
-19.91M▲ 26.5%
-21.3M▼ 7.0%
-24.53M▼ 15.2%
-33.85M▼ 38.0%
-38.18M▼ 12.8%
-12.41M▲ 67.5%
660K▲ 105.3%
-1.62M▲ 0%
Operating Margin %
-669.06%-794.57%-1260%-1294.23%-690.04%-1245.05%-1849.01%-33.36%0.77%-1.79%
Operating Income Growth %
-10.49%-49.03%26.46%-7.01%-15.15%-38%-12.79%67.5%105.32%-
EBITDA
-17.86M-26.63M-19.66M-21.14M-24.39M-33.72M-37.78M-12.18M1.01M-1.29M
EBITDA Margin %
-657.64%-781.54%-1244.24%-1284.08%-685.94%-1240.2%-1829.69%-32.74%1.18%-1.43%
EBITDA Growth %
-10.66%-49.13%26.17%-7.51%-15.37%-38.29%-12.05%67.76%108.28%-4.29%
D&A (Non-Cash Add-back)
310K444K249K167K146K132K399K229K349K330K
EBIT
-23.41M-11.26M-4.13M-23.98M-24.46M-33.82M-38.18M-12.41M3.51M-6K
Net Interest Income
-21.7M-7.96M-4.75M-175K-1.19M-2.69M-1.44M02.92M2.44M
Interest Income
000000002.92M2.44M
Interest Expense
21.7M7.96M4.75M175K1.19M2.69M1.44M000
Other Income/Expense
-26.95M7.85M11.03M-2.85M-1.12M-2.65M-9.5M-13.98M2.85M2.96M
Pretax Income
-45.12M▲ 0%
-19.22M▲ 57.4%
-8.88M▲ 53.8%
-24.16M▼ 172.1%
-25.65M▼ 6.2%
-36.51M▼ 42.3%
-47.68M▼ 30.6%
-26.39M▲ 44.7%
3.51M▲ 113.3%
1.34M▲ 0%
Pretax Margin %
-1661.77%-564.19%-561.96%-1467.56%-721.49%-1342.7%-2308.86%-70.92%4.12%1.48%
Income Tax
00000000810K777K
Effective Tax Rate %
0%0%0%0%0%0%0%0%23.08%58.07%
Net Income
-45.12M▲ 0%
-19.22M▲ 57.4%
-8.88M▲ 53.8%
-24.16M▼ 172.1%
-25.65M▼ 6.2%
-36.51M▼ 42.3%
-47.68M▼ 30.6%
-26.39M▲ 44.7%
2.7M▲ 110.2%
561K▲ 0%
Net Margin %
-1661.77%-564.19%-561.96%-1467.56%-721.49%-1342.7%-2308.86%-70.92%3.17%0.62%
Net Income Growth %
-151.05%57.4%53.81%-172.06%-6.18%-42.34%-30.6%44.66%110.23%103.95%
Net Income (Continuing)
-45.12M-19.22M-8.88M-24.16M-25.65M-36.51M-47.68M-26.39M2.7M561K
Discontinued Operations
0000000000
Minority Interest
0000000000
EPS (Diluted)
-999999.00▲ 0%
-503.85▲ 99.9%
-342.82▲ 32.0%
-8.35▲ 97.6%
-3.59▲ 57.0%
-4.12▼ 14.7%
-2.94▲ 28.7%
-0.93▲ 68.5%
0.07▲ 107.3%
0.02▲ 0%
EPS Growth %
99.83%99.98%31.96%97.56%57.04%-14.74%28.67%68.5%107.3%101.19%
EPS (Basic)
-999999.00-503.85-342.82-8.35-3.59-4.12-2.94-0.930.08-
Diluted Shares Outstanding
2038.15K25.9K2.9M7.15M8.86M16.23M28.51M39.92M36.02M
Basic Shares Outstanding
2038.15K25.9K2.9M7.15M8.86M16.23M28.51M35.82M36.02M
Dividend Payout Ratio
----------

DCTH Balance Sheet

Delcath Systems, Inc. (DCTH) balance sheet — assets, liabilities & shareholders' equity

MetricDec'17Dec'18Dec'19Dec'20Dec'21Dec'22Dec'23Dec'24Dec'25TTM
Total Current Assets
7.59M5.92M12.62M32.34M31.15M16.16M37.16M73.76M119.53M120.27M
Cash & Short-Term Investments
4M2.52M10M28.57M22.8M7.67M32.45M53.23M91.04M89.3M
Cash Only
4M2.52M10M28.57M22.8M7.67M12.65M32.41M43.45M41.31M
Short-Term Investments
00000019.81M20.82M47.58M47.99M
Accounts Receivable
317K1.16M21K57K44K366K483K11.06M11.74M14.16M
Days Sales Outstanding
42.62124.74.8512.644.5249.1385.37108.550.2957.65
Inventory
1.25M858K654K855K1.41M2M3.32M6.93M10.25M9.81M
Days Inventory Outstanding
649.81310.38332487.62768.081.06K1.91K408.94317.2297.22
Other Current Assets
1.47M1.19M626K509K4.36M4.25M387K1.39M6.5M7M
Total Non-Current Assets
1.3M925K1.59M2.3M1.97M1.71M1.46M2.83M4.1M4.57M
Property, Plant & Equipment
1.3M925K1.59M2.3M1.97M1.71M1.46M2.83M4.1M4.57M
Fixed Asset Turnover
2.09x3.68x0.99x0.72x1.80x1.59x1.42x13.15x20.78x22.98x
Goodwill
0000000000
Intangible Assets
0000000000
Long-Term Investments
0000000000
Other Non-Current Assets
0000000000
Total Assets
8.89M▲ 0%
6.84M▼ 23.0%
14.21M▲ 107.7%
34.63M▲ 143.7%
33.12M▼ 4.4%
17.86M▼ 46.1%
38.61M▲ 116.2%
76.59M▲ 98.4%
123.63M▲ 61.4%
124.84M▲ 0%
Asset Turnover
0.31x0.50x0.11x0.05x0.11x0.15x0.05x0.49x0.69x0.74x
Asset Growth %
-74.78%-22.99%107.66%143.7%-4.36%-46.08%116.17%98.35%61.42%641.36%
Total Current Liabilities
7.81M17.75M15.99M10.04M5.95M14.73M16.45M6.14M10.95M10.7M
Accounts Payable
3.85M7.71M4.53M1.77M638K2.02M1.01M961K2.66M3.46M
Days Payables Outstanding
2K2.79K2.3K1.01K347.051.07K581.756.6882.2493.28
Short-Term Debt
02.04M02M621K7.85M10.15M0092K
Deferred Revenue (Current)
03.4M482K525K170K00000
Other Current Liabilities
2.84M6.21M9.39M4.3M2.41M1.04M1.93M3.71M8.19M7.14M
Current Ratio
0.97x0.33x0.79x3.22x5.23x1.10x2.26x12.01x10.92x11.24x
Quick Ratio
0.81x0.29x0.75x3.14x4.99x0.96x2.06x10.88x9.98x10.33x
Cash Conversion Cycle
-1.31K-2.36K-1.96K-511.48425.5538.491.41K460.76285.25261.59
Total Non-Current Liabilities
395K4.03M4.58M2.52M15.22M8.99M6.39M1.7M1.46M1.43M
Long-Term Debt
002M015.01M7.84M000815K
Capital Lease Obligations
00197K450K207K00933K835K2.57M
Deferred Tax Liabilities
0000000000
Other Non-Current Liabilities
395K628K0001.14M6.39M766K628K615K
Total Liabilities
8.21M21.78M20.57M12.56M21.17M23.72M22.84M7.84M12.41M12.13M
Total Debt
02.04M2.86M2.94M16.25M15.87M10.19M1.04M936K907K
Net Debt
-4M-478K-7.14M-25.63M-6.55M8.2M-2.46M-31.37M-42.52M-40.41M
Debt / Equity
---0.13x1.36x-0.65x0.02x0.01x0.01x
Debt / EBITDA
--------0.93x-0.70x
Net Debt / EBITDA
---------42.14x31.35x
Interest Coverage
-1.08x-1.42x-0.87x-137.03x-20.63x-12.60x-26.53x---
Total Equity
678K▲ 0%
-14.94M▼ 2303.4%
-6.36M▲ 57.4%
22.08M▲ 447.3%
11.95M▼ 45.9%
-5.86M▼ 149.0%
15.78M▲ 369.3%
68.75M▲ 335.7%
111.22M▲ 61.8%
112.71M▲ 0%
Equity Growth %
145.5%-2303.39%57.45%447.3%-45.86%-149.02%369.28%335.74%61.78%3746.65%
Book Value per Share
33772.94-391.59-245.447.621.67-0.660.972.412.793.13
Total Shareholders' Equity
678K-14.94M-6.36M22.08M11.95M-5.86M15.78M68.75M111.22M112.71M
Common Stock
1.14M103K1K60K79K100K228K331K347K344K
Retained Earnings
-324.83M-344.05M-371.17M-395.33M-420.98M-457.48M-505.16M-531.55M-528.85M-529.92M
Treasury Stock
-51K000000000
Accumulated OCI
42K50K28K-104K18K-83K135K82K575K571K
Minority Interest
0000000000

DCTH Cash Flow Statement

Delcath Systems, Inc. (DCTH) cash flow — operating, investing & free cash flow history

MetricDec'17Dec'18Dec'19Dec'20Dec'21Dec'22Dec'23Dec'24Dec'25TTM
Cash from Operations
-15.4M-14.73M-23.69M-22.87M-22.6M-24.95M-31.25M-18.68M22.52M21.17M
Operating CF Margin %
-567.15%-432.4%-1499.3%-1389.31%-635.84%-917.62%-1513.37%-50.21%26.42%-
Operating CF Growth %
-8.34%4.33%-60.8%3.47%1.15%-10.38%-25.25%40.22%220.53%1353.73%
Net Income
-45.12M-19.22M-8.88M-24.16M-25.65M-36.51M-47.68M-26.39M2.7M561K
Depreciation & Amortization
310K444K249K192K146K132K128K229K349K413K
Stock-Based Compensation
129K58K277K3.91M7.83M7.94M8.15M9.77M24.23M11.72M
Deferred Taxes
5.23M-15.76M02.83M000000
Other Non-Cash Items
21.54M7.97M-9.77M159K831K1.37M9.05M13.23M-1.7M8.76M
Working Capital Changes
2.51M11.77M-5.56M-5.81M-5.76M2.11M-906K-15.52M-3.07M-289K
Change in Receivables
108K-293K497K-36K13K-322K125K-10.65M-854K-217K
Change in Inventory
-543K385K204K-201K-557K-587K-1.32M-3.61M-3.32M-2.68M
Change in Payables
3.18M8.18M-4.79M-5.31M-1.14M1.8M-199K479K4.77M5.42M
Cash from Investing
-524K-76K-24K-782K-143K-209K-19.71M-981K-26.59M-2.01M
Capital Expenditures
-524K-76K-24K-782K-143K-209K-58K-559K-1.55M-1.98M
CapEx % of Revenue
19.3%2.23%1.52%47.51%4.02%7.69%2.81%1.5%1.82%2.19%
Acquisitions
0000000000
Investments
----------
Other Investing
0000000000
Cash from Financing
15.45M13.24M30.3M42.35M20.82M10.14M51.78M39.41M15.05M9.41M
Debt Issued (Net)
0794K3.68M-26K14.44M-714K-6.31M-10.61M00
Equity Issued (Net)
0026.63M39.76M3.92M10.86M23.08M7.02M15.05M9.41M
Dividends Paid
-527K000000000
Share Repurchases
00000000-6M-9M
Other Financing
2.85M12.44M02.62M2.46M035.01M43M00
Net Change in Cash
-410K▲ 0%
-1.75M▼ 325.9%
6.61M▲ 478.4%
18.57M▲ 181.2%
-1.8M▼ 109.7%
-15.13M▼ 739.2%
874K▲ 105.8%
19.72M▲ 2155.8%
11.04M▼ 44.0%
28.54M▲ 0%
Free Cash Flow
-15.92M▲ 0%
-14.81M▲ 7.0%
-23.71M▼ 60.1%
-23.65M▲ 0.3%
-22.75M▲ 3.8%
-25.16M▼ 10.6%
-31.31M▼ 24.4%
-19.24M▲ 38.5%
20.97M▲ 209.0%
19.19M▲ 0%
FCF Margin %
-586.45%-434.63%-1500.82%-1436.82%-639.86%-925.3%-1516.17%-51.71%24.6%21.22%
FCF Growth %
-10.03%7%-60.14%0.27%3.82%-10.6%-24.44%38.55%208.99%353.21%
FCF per Share
-793116.15-388.15-915.56-8.16-3.18-2.84-1.93-0.670.530.53
FCF Conversion (FCF/Net Income)
0.34x0.77x2.67x0.95x0.88x0.68x0.66x0.71x8.34x34.21x
Interest Paid
0000000000
Taxes Paid
0000000000

DCTH Key Ratios

Delcath Systems, Inc. (DCTH) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios

Metric201720182019202020212022202320242025TTM
Return on Equity (ROE)
-6654.42%---307.31%-150.74%-1198.36%-961.44%-62.44%3%0.51%
Return on Invested Capital (ROIC)
-660.87%----1985.78%-655.3%-365.68%-36.72%0.93%-1.69%
Gross Margin
74.18%70.38%54.49%61.12%81.13%74.77%69.25%83.37%86.16%85.97%
Net Margin
-1661.77%-564.19%-561.96%-1467.56%-721.49%-1342.7%-2308.86%-70.92%3.17%0.62%
Debt / Equity
---0.13x1.36x-0.65x0.02x0.01x0.01x
Interest Coverage
-1.08x-1.42x-0.87x-137.03x-20.63x-12.60x-26.53x---
FCF Conversion
0.34x0.77x2.67x0.95x0.88x0.68x0.66x0.71x8.34x34.21x
Revenue Growth
36.3%25.49%-53.62%4.18%115.98%-23.52%-24.05%1701.69%129.08%67.95%
Related:DCTH Dividend History·DCTH Revenue History·DCTH Price History·DCTH P/E History·DCTH Financial Ratios·DCTH Institutional Holders

DCTH SEC Filings & Documents

Delcath Systems, Inc. (DCTH) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

May 14, 2026·SEC

Material company update

May 7, 2026·SEC

Material company update

Mar 3, 2026·SEC

10-K Annual Reports

3
FY 2026

Feb 26, 2026·SEC

FY 2025

Mar 6, 2025·SEC

FY 2024

Mar 26, 2024·SEC

10-Q Quarterly Reports

6
FY 2026

May 7, 2026·SEC

FY 2025

Nov 4, 2025·SEC

FY 2025

Aug 6, 2025·SEC

DCTH Frequently Asked Questions

Delcath Systems, Inc. (DCTH) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials

Delcath Systems, Inc. (DCTH) reported $90.4M in revenue for fiscal year 2025.

Delcath Systems, Inc. (DCTH) grew revenue by 129.1% over the past year. This is strong growth.

Yes, Delcath Systems, Inc. (DCTH) is profitable, generating $0.6M in net income for fiscal year 2025 (3.2% net margin).

Dividend & Returns

Delcath Systems, Inc. (DCTH) has a return on equity (ROE) of 3.0%. This is below average, suggesting room for improvement.

Delcath Systems, Inc. (DCTH) generated $19.2M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

What if you invested $1,000 in DCTH back in 1999?

Total return calculator · dividends reinvested · 27+ years of data

See returns →

How much would $100/month in DCTH be worth today?

Dollar cost averaging calculator · DCA vs lump sum

Calculate →